le l 1 IDH Morsa Images Exelixis, Inc. (NASDAQ:EXEL) released its earnings report for its second-quarter 2024 earnings. Investors should look into this name because Cabometyx has been holding strong in treating patients with Renal Cell Carcinoma [RCC]. Matter of fact, U.S. net product revenues grew by 16% quarter over quarter. Furthermore, a 7% growth of this was attributed year over year as well. Revenue for this franchise is coming along so well that it was able to receive a $150 million sales-based miles ...